Plant Platforms for Efficient Heterologous Protein Production

Area of Science:

• Biotechnology
• Molecular Biology
• Pharmaceutical Sciences

Background:

• Traditional recombinant protein production relies on microbial, insect, and mammalian cell cultures.
• Plant-based systems offer potential advantages in speed, scale, and cost for pharmaceutical production.
• Growing interest in utilizing plants for high-value biologics, including vaccines and antibodies.

Purpose of the Study:

• To review advancements in plant-based pharmaceutical production over the past two decades.
• To highlight recent developments and achievements in plant-derived therapeutics.
• To discuss strategies for enhancing protein production in plants for commercial viability.

Main Methods:

• Exploration of novel plant transformation technologies: plastid engineering, agroinfiltration, magnifection, and viral vectors.
• Analysis of clinical trial data for plant-produced vaccines and antibodies.
• Review of strategies to optimize yield and quality of therapeutic proteins in plants.

Main Results:

• Several plant-produced vaccines and antibodies have successfully completed Phase I human clinical trials.
• Plant-derived therapeutics are progressing towards regulatory approval for large-scale manufacturing.
• Advanced technologies significantly enhance protein production efficiency and scalability in plant systems.

Conclusions:

• Plant-based production of therapeutic proteins is a pragmatic and increasingly viable approach.
• Plant-derived biologics demonstrate safety, efficacy, and potential for meeting quality standards.
• Continued innovation in plant biotechnology can make these systems highly competitive with established methods.